Tanabe Seiyaku Explores Possible Merger with Mitsubishi Pharma
Tokyo (Jan. 18)-Tanabe Seiyaku Co. Ltd. confirmed it has had discussions with Mitsubishi Pharma Corporation over a possible merger between the two companies, but that no definite decision has been made for such a deal.
Tokyo (Jan. 18)-Tanabe Seiyaku Co. Ltd. (www.tanabe.co.jp/english) confirmed it has had discussions with Mitsubishi Pharma Corporation (www.m-pharma.co.jp) over a possible merger between the two companies, but that no definite decision has been made for such a deal.
“Tanabe has been discussing with Mitsubishi Pharma on a potential merger between the two companies for the purpose of expansion of business scale and reinforcement of management infrastructure to respond to the competitive environment surrounding the pharmaceutical market and survive intensifying global competition,” said Tanabe Seiyaku in a prepared statement. “However, no concrete decision has been made in this regard.”
A potential merger between Tanabe Seiyaku and Mitsubishi Pharma follows recent consolidation in the Japanese pharmaceutical industry. In 2005, Sanyko and Daiichi Pharmaceuticals merged to form Daiichi Sanyko Co. Ltd. (Tokyo, www.daiichipharm.co.jp/english), and Fujisawa Pharmaceutical Co., Ltd. and Yamanouchi Pharmaceutical Co., Ltd. merged to form Astellas Pharma Inc. (Tokyo, www.astellas.com).
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
